IMPD and Investigator Brochure MCQs With Answer

IMPD and Investigator Brochure MCQs With Answer

The Investigational Medicinal Product Dossier (IMPD) and the Investigator’s Brochure (IB) are central to clinical trial approvals and conduct in Regulatory Affairs. This quiz is designed to help M. Pharm students master practical nuances: how the IMPD maps to CTD modules, QP certification, comparator and placebo documentation, stability expectations, substantial amendments, and the structure and maintenance of the IB as per ICH E6(R2). You’ll also test your knowledge on labeling requirements under EU GMP Annex 13/CTR, cross-referencing to ASMF/CEP, environmental risk considerations for ATMPs, and alignment with DSUR. Each question targets regulatory reasoning and decision-making you will need in dossier preparation, submissions, and site support.

Q1. What is the primary purpose of the IMPD in an EU clinical trial application?

• Describe recruitment strategies and site feasibility
• Provide detailed quality, nonclinical, and clinical information about the IMP to assess safety and quality for trial authorization
• Present marketing claims and promotional materials for the IMP
• Set pricing and reimbursement assumptions for the IMP

Correct Answer: Provide detailed quality, nonclinical, and clinical information about the IMP to assess safety and quality for trial authorization

Q2. Which CTD modules are reflected in the structure of the IMPD?

• Module 1 only
• Module 3 only
• Modules 2, 3, 4, and 5
• Modules 1 to 5

Correct Answer: Modules 2, 3, 4, and 5

Q3. Where is the Quality Overall Summary (QOS)-style summary for an IMP placed in an IMPD?

• Within Module 2, summarizing data from Module 3
• Within Module 1, as a regional administrative document
• Within Module 5, as part of clinical summaries
• Within the Investigator’s Brochure instead of the IMPD

Correct Answer: Within Module 2, summarizing data from Module 3

Q4. What is required for batch certification and release of an IMP in the EU?

• Certification by a Qualified Person (QP) in accordance with EU GMP Annex 13
• Certification by the Principal Investigator
• Certification by the Sponsor’s Medical Monitor
• No certification is required if the IMP is an authorized product

Correct Answer: Certification by a Qualified Person (QP) in accordance with EU GMP Annex 13

Q5. Which statement about the Investigator’s Brochure (IB) is correct according to ICH E6(R2)?

• It is a marketing document intended for prescribers post-approval
• It contains comprehensive summaries of nonclinical and clinical data to inform investigators on the rationale, dosing, safety, and risk mitigation
• It contains only chemistry and manufacturing information
• It replaces the clinical protocol in providing operational trial conduct details

Correct Answer: It contains comprehensive summaries of nonclinical and clinical data to inform investigators on the rationale, dosing, safety, and risk mitigation

Q6. How frequently should the Investigator’s Brochure be reviewed and updated?

• Every five years, regardless of new information
• Only when a trial is completed
• At least annually and whenever important new safety or efficacy information becomes available
• Only prior to the first patient enrollment

Correct Answer: At least annually and whenever important new safety or efficacy information becomes available

Q7. For an EU-authorized comparator used as an IMP without modification, which documentation is typically acceptable instead of full quality data in the IMPD?

• The current EU Summary of Product Characteristics (SmPC) as a simplified IMPD
• A copy of the product’s price list
• The Investigator’s curriculum vitae
• The Development Safety Update Report (DSUR)

Correct Answer: The current EU Summary of Product Characteristics (SmPC) as a simplified IMPD

Q8. What stability information is expected in the IMPD to justify the proposed shelf-life?

• Only accelerated stability data at 40°C/75% RH
• Stability-indicating methods, relevant long-term/accelerated data supporting shelf-life and storage conditions, and in-use stability if applicable
• No stability data are needed for blinded trials
• Only vendor certificates of analysis

Correct Answer: Stability-indicating methods, relevant long-term/accelerated data supporting shelf-life and storage conditions, and in-use stability if applicable

Q9. Which change typically qualifies as a substantial amendment to the IMPD requiring prior approval?

• Correction of typographical errors in the IB
• Change in the IMP drug product manufacturing site that could impact quality
• Update to a monitor’s contact details
• Adding a new sub-investigator at a site

Correct Answer: Change in the IMP drug product manufacturing site that could impact quality

Q10. Which statement best differentiates the IB from the SmPC?

• The IB is a post-approval prescribing document; the SmPC is pre-approval
• The IB targets investigators with comprehensive preclinical and clinical summaries; the SmPC targets prescribers with authorized product information
• The IB and SmPC contain identical content
• The SmPC includes nonclinical study reports; the IB does not

Correct Answer: The IB targets investigators with comprehensive preclinical and clinical summaries; the SmPC targets prescribers with authorized product information

Q11. Which annual safety document complements and informs updates to the IB during development?

• Risk Management Plan (RMP)
• Periodic Safety Update Report (PSUR)
• Development Safety Update Report (DSUR)
• Clinical Study Report (CSR)

Correct Answer: Development Safety Update Report (DSUR)

Q12. In blinded trials, which quality consideration should be documented in the IMPD?

• Lack of patient access to the EDC system
• Specifications and controls ensuring indistinguishability between IMP and matching placebo/comparator
• Site pharmacy staffing levels
• Advertising materials for recruitment

Correct Answer: Specifications and controls ensuring indistinguishability between IMP and matching placebo/comparator

Q13. How can proprietary drug substance information be adequately supported in an IMPD?

• By providing only the sponsor’s cover letter
• By including a Letter of Access to an ASMF or submitting a valid CEP for the active substance
• By excluding drug substance details entirely
• By referencing a conference abstract

Correct Answer: By including a Letter of Access to an ASMF or submitting a valid CEP for the active substance

Q14. Which element is mandatory on EU IMP labeling under GMP Annex 13/CTR requirements?

• Retail price
• Patient’s medical history
• “For clinical trial use only” (or equivalent wording)
• Sponsor’s profit margin

Correct Answer: “For clinical trial use only” (or equivalent wording)

Q15. Can nonclinical and clinical sections of the IMPD be satisfied by cross-referencing the Investigator’s Brochure?

• No, full study reports must always be included in the IMPD
• Yes, a cross-reference to the IB is acceptable, provided sufficient summaries and references are available
• Only nonclinical sections can be cross-referenced
• Only clinical sections can be cross-referenced

Correct Answer: Yes, a cross-reference to the IB is acceptable, provided sufficient summaries and references are available

Q16. Which document typically includes detailed site-level handling, reconstitution, and administration instructions beyond what is in the IB/IMPD?

• The Case Report Form (CRF)
• The Pharmacy Manual or Site Pharmacy Handbook
• The Statistical Analysis Plan (SAP)
• The EudraCT/CTIS Registration Form

Correct Answer: The Pharmacy Manual or Site Pharmacy Handbook

Q17. Which is an appropriate expectation for IMP drug product specifications in the IMPD?

• Only appearance and odor tests are required
• Specifications should be stability-indicating and include identity, assay, impurities, and microbiological tests as appropriate
• No microbial limits are allowed for sterile products
• Release testing can be omitted if stability data are robust

Correct Answer: Specifications should be stability-indicating and include identity, assay, impurities, and microbiological tests as appropriate

Q18. For a gene therapy IMP in the EU, what additional assessment is commonly required as part of the clinical trial application?

• Only a pricing dossier
• Environmental Risk Assessment addressing GMO considerations
• A Phase IV pharmacovigilance plan
• Bioequivalence study report

Correct Answer: Environmental Risk Assessment addressing GMO considerations

Q19. Which statement about language requirements is generally correct in EU clinical trials?

• The IMP label must be in the national language(s) as per Member State requirements
• The IMP label can only be in Latin
• The IB must always be translated into all EU languages
• The IMPD must be in the investigator’s native language

Correct Answer: The IMP label must be in the national language(s) as per Member State requirements

Q20. In the IB, which section provides the investigator with an assessment of overall benefit–risk and practical safety guidance for study conduct?

• Table of Contents
• CMC/Quality Information
• Guidance for the Investigator
• List of Abbreviations

Correct Answer: Guidance for the Investigator

Download